These data suggest that TREM-1-specific peptide inhibitors have a cancer type-independent anti-tumor activity and can potentially be used as a stand-alone therapy or as a component of combinational therapy for several types of solid tumors. This evidence concerns the gene TREM1 and neoplasm.